AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28807486 — intervention group
Group type: EXPERIMENTAL
Intervention: Women living alone or divorced
Number of subjects: 1193
Study 28807486 — intervention group
Group type: COMPARATOR
Intervention: Women married
Number of subjects: 1193
Study 25998123 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 51
Study 25998123 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual Care plus Voiceover Interactive PowerPoint (UC+VOIPP)
Number of subjects: 51
Study 24239044 — intervention group
Group type: EXPERIMENTAL
Intervention: TT4 (n=180)
Number of subjects: 267
Study 24239044 — intervention group
Group type: COMPARATOR
Intervention: Current standard-of-care (SoC, n=87)
Number of subjects: 267
Study 24239044 — intervention group
Group type: EXPERIMENTAL
Intervention: TT4 (G1 subgroup)
Number of subjects: 267
Study 24239044 — intervention group
Group type: COMPARATOR
Intervention: SoC (G1 subgroup)
Number of subjects: 267
Study 24239044 — intervention group
Group type: EXPERIMENTAL
Intervention: TT4 (G2 subgroup)
Number of subjects: 267
Study 24239044 — intervention group
Group type: COMPARATOR
Intervention: SoC (G2 subgroup)
Number of subjects: 267
Study 24239044 — intervention group
Group type: EXPERIMENTAL
Intervention: TT4 (G3 subgroup)
Number of subjects: 267
Study 24239044 — intervention group
Group type: COMPARATOR
Intervention: SoC (G3 subgroup)
Number of subjects: 267
Study 24239044 — intervention group
Group type: EXPERIMENTAL
Intervention: TT4 (G4 subgroup)
Number of subjects: 267
Study 24239044 — intervention group
Group type: COMPARATOR
Intervention: SoC (G4 subgroup)
Number of subjects: 267
Study 22593697 — intervention group
Group type: EXPERIMENTAL
Intervention: LPNIR plus nerve block (NB) or local block (LB)
Number of subjects: 52
Study 22593697 — intervention group
Group type: COMPARATOR
Intervention: Control group (NB or LB without LPNIR)
Number of subjects: 52
Study 22593697 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (I and C)
Number of subjects: 52
Study 19948506 — intervention group
Group type: EXPERIMENTAL
Intervention: Vernakalant (3 mg/kg infusion for 10 minutes, followed by 2 mg/kg if needed)
Number of subjects: 150
Study 19948506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 19948506 — intervention group
Group type: EXPERIMENTAL
Intervention: Vernakalant
Number of subjects: 150
Study 17321387 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual microphacoemulsification
Number of subjects: 50
Study 17321387 — intervention group
Group type: COMPARATOR
Intervention: Coaxial miniphacoemulsification
Number of subjects: 50
Study 15346702 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 75 microg/kg
Number of subjects: 82
Study 15346702 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 82
Study 11583479 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 5 mg
Number of subjects: 12
Study 11583479 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 10 mg
Number of subjects: 12
Study 11583479 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 20 mg
Number of subjects: 12
Study 11583479 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 40 mg
Number of subjects: 12
Study 11583479 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg
Number of subjects: 12
Study 11583479 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib (5-120 mg range)
Number of subjects: 12
Study 9836104 — intervention group
Group type: EXPERIMENTAL
Intervention: IgA anti‐transglutaminase antibodies by enzyme‐linked immunosorbent assay test
Number of subjects: 41
Study 8015820 — intervention group
Group type: EXPERIMENTAL
Intervention: BV (Immunomodulation therapy)
Number of subjects: 120
Study 8015820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 2892450 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg
Number of subjects: 10
Study 2892450 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 10
Study 2892450 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 20 mg
Number of subjects: 10
Study 2892450 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine 25 mg
Number of subjects: 10
Study 2892450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29333910 — intervention group
Group type: EXPERIMENTAL
Intervention: Plano contact lenses (CL)
Number of subjects: 38
Study 29333910 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully corrective contact lenses (CL)
Number of subjects: 38
Study 26474041 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg twice daily)
Number of subjects: 50
Study 26474041 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (500 mg twice daily)
Number of subjects: 50
Study 24471868 — intervention group
Group type: COMPARATOR
Intervention: Alfuzosin 10 mg alone (Group A)
Number of subjects: 135
Study 24471868 — intervention group
Group type: COMPARATOR
Intervention: Alfuzosin 10 mg plus Propiverine 10 mg (Group B)
Number of subjects: 135
Study 24471868 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg plus Propiverine 20 mg (Group C)
Number of subjects: 135
Study 22172432 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 120
Study 22172432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 20799359 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (80 ppm)
Number of subjects: 18
Study 20799359 — intervention group
Group type: COMPARATOR
Intervention: Placebo (21% O2)
Number of subjects: 18
Study 18599577 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete proximal MCA recanalization
Number of subjects: 44
Study 18599577 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete proximal MCA recanalization
Number of subjects: 44
Study 19455984 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusions of 400 ml of ozonized sodium chloride solution (pO3) containing 1.6 microg/ml of O3 twice weekly for 21 days
Number of subjects: 36
Study 19455984 — intervention group
Group type: COMPARATOR
Intervention: Control group (antibacterial therapy only)
Number of subjects: 36
Study 19455984 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood ozonization in combination with antibiotics
Number of subjects: 36
Study 19455984 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone therapy
Number of subjects: 36
Study 15938923 — intervention group
Group type: COMPARATOR
Intervention: CPT‐11 90 ‐ 25 mg/m(2) continuous infusion for 10 h and folinic acid (FA) 30 mg x m(‐2) x d(‐1) + 5‐FU 425 mg x m(‐2) x d(‐1) x 2 d continuous infusion for 48 h, every two weeks for a total of no less than six cycles (Group A)
Number of subjects: 43
Study 15938923 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT‐11 90 ‐ 125 mg/m(2) continuous infusion for 10 h every two weeks for a total of no less than six cycles and capecitabine 1250 mg x m(‐2) x d(‐1) by oral divided into two doses, continuously taken without interruption for three months (Group B)
Number of subjects: 43
Study 11285130 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR-based typing (PCR-SSOP or PCR-SSP)
Number of subjects: 42160
Study 11285130 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR-based typing
Number of subjects: 42160
Study 9137123 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (200 mg i.v.)
Number of subjects: 16
Study 9137123 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 16
Study 8498465 — intervention group
Group type: EXPERIMENTAL
Intervention: Life review reminiscence activities
Number of subjects: 24
Study 8498465 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 24
Study 3479848 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel
Number of subjects: 50
Study 3479848 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin infusion
Number of subjects: 50
Study 31436231 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous RFA plus intravenous infusion of LTLD (combination group, n = 11)
Number of subjects: 18
Study 31436231 — intervention group
Group type: COMPARATOR
Intervention: RFA plus IV dummy (RFA group, n = 11)
Number of subjects: 18
Study 31436231 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of coagulation volume
Number of subjects: 18
Study 28688239 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis (n = 13)
Number of subjects: 28
Study 28688239 — intervention group
Group type: COMPARATOR
Intervention: Non-plasmapheresis (n = 15)
Number of subjects: 28
Study 27086573 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer sealant (GIS)
Number of subjects: 40
Study 27086573 — intervention group
Group type: COMPARATOR
Intervention: Resin-based sealant (RS)
Number of subjects: 40
Study 24365196 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 57
Study 24365196 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (MT)
Number of subjects: 57
Study 23082846 — intervention group
Group type: EXPERIMENTAL
Intervention: ProDisc-L total disc replacement (TDR)
Number of subjects: 236
Study 23082846 — intervention group
Group type: COMPARATOR
Intervention: Circumferential arthrodesis (fusion)
Number of subjects: 236
Study 19943947 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine 4 mg gum or nicotine 10 mg inhaler
Number of subjects: 314
Study 19943947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study 17378202 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Fenglong (ST 40) for TG
Number of subjects: 54
Study 17378202 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Fenglong (ST 40) for TC
Number of subjects: 54
Study 17378202 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Fenglong (ST 40) for LDL-C
Number of subjects: 54
Study 15250817 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirically Supported Therapies (ESTs)
Number of subjects: 0
Study 15250817 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Controlled Trial (RCT) methodology
Number of subjects: 0
Study 15250817 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting practices
Number of subjects: 0
Study 15250817 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative methodologies
Number of subjects: 0
Study 15250817 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing intervention strategies and theories of change
Number of subjects: 0
Study 11675905 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg tablet daily for 5 days)
Number of subjects: 575
Study 11675905 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav (625 mg tablets three times daily for 7 days)
Number of subjects: 575
Study 11675905 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 575
Study 11675905 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav
Number of subjects: 575
Study 9041571 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (3 mg.kg‐1)/propofol bolus (0.5 mg.kg‐1 every 3 min)
Number of subjects: 100
Study 7705855 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon alpha-2a plus podophyllin 25% W/V administered twice per week, preceded by IFN alpha-2a three times weekly for one week
Number of subjects: 124
Study 7705855 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus podophyllin 25% W/V administered in the same schedule
Number of subjects: 124
Study 3311619 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrostep (new graduated estrogen formulation)
Number of subjects: 426
Study 3311619 — intervention group
Group type: COMPARATOR
Intervention: Loestrin 1/20, Loestrin 1.5/30, Norlestrin 1/50 (constant-dosed oral contraceptives)
Number of subjects: 426
Study 3311619 — intervention group
Group type: COMPARATOR
Intervention: All four combination oral contraceptives
Number of subjects: 426
Study 29685614 — intervention group
Group type: EXPERIMENTAL
Intervention: Online nutrition training
Number of subjects: 36
Study 29685614 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 27400002 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed physician rounding (8-10 AM)
Number of subjects: 152
Study 27400002 — intervention group
Group type: COMPARATOR
Intervention: Early physician rounding (5-7 AM)
Number of subjects: 152
Study 25138784 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (600 mg)
Number of subjects: 90
Study 25138784 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam (8 mg)
Number of subjects: 90
Study 25138784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 22106360 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR pacing
Number of subjects: 1415
Study 22106360 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PQ-interval >180 ms
Number of subjects: 1415
Study 22106360 — intervention group
Group type: COMPARATOR
Intervention: %VP
Number of subjects: 1415
Study 22106360 — intervention group
Group type: COMPARATOR
Intervention: Minimal-paced programmed AVI ≤ 100 ms
Number of subjects: 1415
Study 20042923 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible nonlinear (FNL) periodized weight training program
Number of subjects: 16
Study 20042923 — intervention group
Group type: COMPARATOR
Intervention: Nonlinear (NL) periodized weight training program
Number of subjects: 16
Study 18053306 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate (30 mmol K-cit/d)
Number of subjects: 85
Study 18053306 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium chloride
Number of subjects: 85
Study 18053306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 15927989 — intervention group
Group type: EXPERIMENTAL
Intervention: Rho-kinase inhibitor fasudil
Number of subjects: 26
Study 15927989 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 26
Study 15927989 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine
Number of subjects: 26
Study 12030694 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant Health and Development Program (IHDP) intervention
Number of subjects: 0
Study 12030694 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 10407221 — intervention group
Group type: EXPERIMENTAL
Intervention: Anabolic-androgenic steroids (AAS) for a mean period of 6.5 weeks
Number of subjects: 18
Study 10407221 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin administration for 5 weeks
Number of subjects: 18
Study 10407221 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hormonal treatment)
Number of subjects: 18
Study 7562292 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureaplasma urealyticum colonization
Number of subjects: 17
Study 7562292 — intervention group
Group type: COMPARATOR
Intervention: Uncolonized neonates
Number of subjects: 17
Study 2147527 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/day toremifene
Number of subjects: 50
Study 2147527 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg/day toremifene
Number of subjects: 50
Study 2147527 — intervention group
Group type: COMPARATOR
Intervention: 40 mg/day tamoxifen
Number of subjects: 50
Study 2147527 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment mentioned)
Number of subjects: 50
Study 6998794 — intervention group
Group type: EXPERIMENTAL
Intervention: Trithiozine (1200 mg/day)
Number of subjects: 50
Study 6998794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30983457 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ethyl chloride anesthetic spray
Number of subjects: 120
Study 30983457 — intervention group
Group type: COMPARATOR
Intervention: 1% lidocaine subdermal injection
Number of subjects: 120
Study 31823822 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with methotrexate (MTX) and zoledronic acid (ZOL)
Number of subjects: 66
Study 31823822 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid (ZOL) monotherapy
Number of subjects: 66
Study 31823822 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) monotherapy
Number of subjects: 66
Study 27658483 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-436
Number of subjects: 150
Study 27658483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 25938628 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 901
Study 25938628 — intervention group
Group type: COMPARATOR
Intervention: No active treatment
Number of subjects: 901
Study 24260254 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned group (desloratadine 5mg + CS)
Number of subjects: 62
Study 24260254 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham-conditioned group (placebo + CS)
Number of subjects: 62
Study 24260254 — intervention group
Group type: COMPARATOR
Intervention: Natural history group
Number of subjects: 62
Study 21272321 — intervention group
Group type: EXPERIMENTAL
Intervention: State mandates for colorectal cancer screening coverage
Number of subjects: 0
Study 21272321 — intervention group
Group type: COMPARATOR
Intervention: No state mandates for colorectal cancer screening coverage
Number of subjects: 0
Study 20193338 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (50 mg p.o. bid) administered on days 1 to 5 after the start of chemotherapy
Number of subjects: 61
Study 20193338 — intervention group
Group type: COMPARATOR
Intervention: Control group (ramosetron 0.3 mg i.v. and metoclopramide 20 mg i.m. 30 min prior to chemotherapy)
Number of subjects: 61
Study 17426226 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled albuterol
Number of subjects: 20
Study 17426226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15083445 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture (n=13)
Number of subjects: 25
Study 15083445 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (n=12)
Number of subjects: 25
Study 11535548 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/day raloxifene
Number of subjects: 143
Study 11535548 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/day raloxifene
Number of subjects: 143
Study 11535548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 11535548 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (both dosages)
Number of subjects: 143
Study 9500490 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 150 mg administered 2 hours before oral contraceptive on pill day 6
Number of subjects: 20
Study 9500490 — intervention group
Group type: COMPARATOR
Intervention: No fluconazole (control)
Number of subjects: 20
Study 7632414 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundic mobilization in Nissen fundoplication
Number of subjects: 25
Study 7632414 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Nissen fundoplication without fundic mobilization
Number of subjects: 25
Study 7632414 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25
Study 2507747 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric high protein diet (16‐22% protein)
Number of subjects: 5
Study 2507747 — intervention group
Group type: COMPARATOR
Intervention: Normal diet with placebo
Number of subjects: 5
Study 341939 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin hydrochloride
Number of subjects: 0
Study 29793550 — intervention group
Group type: EXPERIMENTAL
Intervention: ipsilateral tilt position
Number of subjects: 237
Study 29793550 — intervention group
Group type: COMPARATOR
Intervention: supine position
Number of subjects: 237
Study 27737678 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium preconditioning (3 × 5 min of 70 % helium and 30 % oxygen)
Number of subjects: 125
Study 27737678 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium postconditioning (15 min of helium)
Number of subjects: 125
Study 27737678 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium pre‐ and postconditioning
Number of subjects: 125
Study 27737678 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane preconditioning
Number of subjects: 125
Study 27737678 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 125
Study 24436209 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Number of subjects: 40
Study 24436209 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 40
Study 24436209 — intervention group
Group type: EXPERIMENTAL
Intervention: US and CT
Number of subjects: 40
Study 22179454 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y (R-Y) anastomosis
Number of subjects: 159
Study 22179454 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic approach
Number of subjects: 159
Study 22179454 — intervention group
Group type: COMPARATOR
Intervention: Billroth I (B-I) anastomosis
Number of subjects: 159
Study 22179454 — intervention group
Group type: COMPARATOR
Intervention: Billroth II (B-II) with Braun anastomosis
Number of subjects: 159
Study 22179454 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 159
Study 20456248 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 U/ml NT 201 dilution
Number of subjects: 192
Study 20456248 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 U/ml NT 201 dilution
Number of subjects: 192
Study 20456248 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dilutions of NT 201
Number of subjects: 192
Study 18827325 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 minutes of passive stretching
Number of subjects: 12
Study 18827325 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 minutes of passive stretching
Number of subjects: 12
Study 18827325 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 minutes of passive stretching
Number of subjects: 12
Study 18827325 — intervention group
Group type: COMPARATOR
Intervention: Control with no stretching
Number of subjects: 12
Study 15943834 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid autoantibodies (TPO‐Ab, Tg‐Ab)
Number of subjects: 4649
Study 12528021 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (32-33 degrees C)
Number of subjects: 28
Study 12528021 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 28